| Dr Ioana D Pencu, MD | |
|
3601 W 13 Mile Rd, Royal Oak, MI 48073-6712 | |
| (248) 691-8646 | |
| Not Available |
| Full Name | Dr Ioana D Pencu |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 26 Years |
| Location | 3601 W 13 Mile Rd, Royal Oak, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295719409 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 4301077727 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Beaumont Hospital, Troy | Troy, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hospital Consultants Pc | 5991698185 | 43 |
News Archive
Can schools safely remain open or reopen during periods of significant community spread of COVID-19? According to predictions from a model of SARS-CoV-2 transmission in the school setting, yes - if appropriate precautions are followed both in school and in the community.
Soft robots that are incredibly light and foldable and can lift weights that are over 1,000 times their own weight and these are also cheap and easy to make costing less than a dollar in making charges.
Sanomedics International Holdings, Inc., a medical technology holding company that focuses on game-changing products, services and ideas, today announced that it has completed the previously announced acquisition of Prime Time Medical, Inc., of Largo, Florida for a total purchase price of $3,100,000, effective August 30, 2013.
The final implementation of the Affordable Care Act (ACA) could be bad news for re-authorization of the Children's Health Insurance Program (CHIP), a congressional staffer said. … Authorization for the program, which provides health coverage to families who make too much to qualify for Medicaid but too little to afford costly health insurance, expires at the end of September 2013.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 41 percent of surveyed European hematologist-oncologists say that the favorable efficacy profile of Roche's MabThera (rituximab) is the most significant driver of their use of this brand, while 26 percent say MabThera's favorable risk-benefit profile is the most significant driver.
› Verified 5 days ago
| Entity Name | Hospital Consultants Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073543013 PECOS PAC ID: 5991698185 Enrollment ID: O20040203000289 |
News Archive
Can schools safely remain open or reopen during periods of significant community spread of COVID-19? According to predictions from a model of SARS-CoV-2 transmission in the school setting, yes - if appropriate precautions are followed both in school and in the community.
Soft robots that are incredibly light and foldable and can lift weights that are over 1,000 times their own weight and these are also cheap and easy to make costing less than a dollar in making charges.
Sanomedics International Holdings, Inc., a medical technology holding company that focuses on game-changing products, services and ideas, today announced that it has completed the previously announced acquisition of Prime Time Medical, Inc., of Largo, Florida for a total purchase price of $3,100,000, effective August 30, 2013.
The final implementation of the Affordable Care Act (ACA) could be bad news for re-authorization of the Children's Health Insurance Program (CHIP), a congressional staffer said. … Authorization for the program, which provides health coverage to families who make too much to qualify for Medicaid but too little to afford costly health insurance, expires at the end of September 2013.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 41 percent of surveyed European hematologist-oncologists say that the favorable efficacy profile of Roche's MabThera (rituximab) is the most significant driver of their use of this brand, while 26 percent say MabThera's favorable risk-benefit profile is the most significant driver.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ioana D Pencu, MD 3601 W 13 Mile Rd, Royal Oak, MI 48073-6712 Ph: (248) 691-8646 | Dr Ioana D Pencu, MD 3601 W 13 Mile Rd, Royal Oak, MI 48073-6712 Ph: (248) 691-8646 |
News Archive
Can schools safely remain open or reopen during periods of significant community spread of COVID-19? According to predictions from a model of SARS-CoV-2 transmission in the school setting, yes - if appropriate precautions are followed both in school and in the community.
Soft robots that are incredibly light and foldable and can lift weights that are over 1,000 times their own weight and these are also cheap and easy to make costing less than a dollar in making charges.
Sanomedics International Holdings, Inc., a medical technology holding company that focuses on game-changing products, services and ideas, today announced that it has completed the previously announced acquisition of Prime Time Medical, Inc., of Largo, Florida for a total purchase price of $3,100,000, effective August 30, 2013.
The final implementation of the Affordable Care Act (ACA) could be bad news for re-authorization of the Children's Health Insurance Program (CHIP), a congressional staffer said. … Authorization for the program, which provides health coverage to families who make too much to qualify for Medicaid but too little to afford costly health insurance, expires at the end of September 2013.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 41 percent of surveyed European hematologist-oncologists say that the favorable efficacy profile of Roche's MabThera (rituximab) is the most significant driver of their use of this brand, while 26 percent say MabThera's favorable risk-benefit profile is the most significant driver.
› Verified 5 days ago
Dr. Cristina Greulich, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-691-8646 | |
Saketh Tummala, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-691-8646 | |
Richard John Bloomingdale, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-898-4163 Fax: 248-898-5596 | |
Parag Somalingam, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-691-8646 | |
Alice Kathleen Makris, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-691-8646 | |
Chloe Habean Kim, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-691-8646 |